Krystal Biotech stock maintains Buy rating at TD Cowen on Vyjuvek label update
PositiveFinancial Markets

Krystal Biotech's stock continues to hold a Buy rating from TD Cowen following an update on the Vyjuvek label. This positive outlook reflects confidence in the company's growth potential.
Editor’s Note: The maintenance of a Buy rating by TD Cowen is significant as it indicates strong investor confidence in Krystal Biotech's future, particularly with the recent updates on Vyjuvek, which could enhance its market position.
— Curated by the World Pulse Now AI Editorial System